- Home
- ENGS vs STTK Comparison
ENGS vs STTK Comparison
Compare ENGS & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGS
- STTK
- Stock Information
- Founded
- ENGS 1998
- STTK 2016
- Country
- ENGS United Kingdom
- STTK United States
- Employees
- ENGS N/A
- STTK N/A
- Industry
- ENGS
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- ENGS
- STTK Health Care
- Exchange
- ENGS NYSE
- STTK Nasdaq
- Market Cap
- ENGS 41.9M
- STTK 37.6M
- IPO Year
- ENGS 2025
- STTK 2020
- Fundamental
- Price
- ENGS $3.05
- STTK $1.01
- Analyst Decision
- ENGS
- STTK Hold
- Analyst Count
- ENGS 0
- STTK 4
- Target Price
- ENGS N/A
- STTK $3.00
- AVG Volume (30 Days)
- ENGS 1.2M
- STTK 100.5K
- Earning Date
- ENGS 01-01-0001
- STTK 05-01-2025
- Dividend Yield
- ENGS N/A
- STTK N/A
- EPS Growth
- ENGS N/A
- STTK N/A
- EPS
- ENGS N/A
- STTK N/A
- Revenue
- ENGS $12,134,254.00
- STTK $4,606,000.00
- Revenue This Year
- ENGS N/A
- STTK N/A
- Revenue Next Year
- ENGS N/A
- STTK N/A
- P/E Ratio
- ENGS N/A
- STTK N/A
- Revenue Growth
- ENGS 59.88
- STTK 69.65
- 52 Week Low
- ENGS $1.46
- STTK $0.69
- 52 Week High
- ENGS $10.24
- STTK $7.57
- Technical
- Relative Strength Index (RSI)
- ENGS N/A
- STTK 50.24
- Support Level
- ENGS N/A
- STTK $0.97
- Resistance Level
- ENGS N/A
- STTK $1.17
- Average True Range (ATR)
- ENGS 0.00
- STTK 0.10
- MACD
- ENGS 0.00
- STTK 0.01
- Stochastic Oscillator
- ENGS 0.00
- STTK 45.21
About ENGS ENERGYS GROUP LTD
Energys Group Ltd provides end-to-end customized solutions and services involving the retrofitting of existing infrastructure to reduce their CO2 emissions. The Company's customers include large national account end-users, including universities, schools, hospitals and electrical distributors in the United Kingdom.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.